LOS ANGELES--(BUSINESS WIRE)--Goldberg Law PC, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Lion Biotechnologies, Inc. (“Lion Biotechnologies” or the “Company”) (Nasdaq: LBIO). Investors who purchased the Company’s shares between November 14, 2013 and April 10, 2017 inclusive (the “Class Period”), are encouraged to contact the firm in advance of the June 13, 2017 lead plaintiff motion deadline.
If you are a shareholder who suffered a loss during the Class Period, click here to participate. In addition, we encourage you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars, Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights free of charge. You can also reach us through the firm’s website at http://www.goldberglawpc.com/, or by email at firstname.lastname@example.org.
The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
The Complaint alleges that during the Class Period, Lion Biotechnologies violated federal securities laws by making materially false and misleading public statements. On April 10, 2017, the U.S. Securities and Exchange Commission found that between September 2013 and March 2014, the Company’s former CEO Manish Singh misled investors by commissioning over 10 internet publications and 20 widely distributed emails promoting Lion Biotechnologies to potential investors that purported to be independent from the Company, when they were actually paid promotions. When this news was announced to the public, the stock price of Lion Biotechnologies dropped, causing investors harm.
Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.